Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
about
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysisEffects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel functionGastrointestinal symptoms and motility disorders in patients with systemic sclerodermaApplying novel nutrient drink to clinical trial of functional dyspepsia.Cyclic stretch disrupts apical junctional complexes in Caco-2 cell monolayers by a JNK-2-, c-Src-, and MLCK-dependent mechanism.Subtypes of functional dyspepsia.Investigation of esophageal sensation and biomechanical properties in functional chest painThe placebo effect in irritable bowel syndrome trials: a meta-analysis.Guidelines for the management of dyspepsia.Irritable bowel syndrome: an integrated explanatory model for clinical practice.Rectal sensorimotor dysfunction in patients with urge faecal incontinence: evidence from prolonged manometric studies.Body mass index and chronic unexplained gastrointestinal symptoms: an adult endoscopic population based study.Functional dyspepsia, delayed gastric emptying, and impaired quality of life.Opiates in the control of gastrointestinal tract function: current knowledge and new avenues for research.Challenges in drug development for functional gastrointestinal disorders. Part II: visceral pain.Rectal hyposensitivity.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Predictors of the placebo response in functional dyspepsia.Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis.Clinical presentation of fecal incontinence and anorectal function: what is the relationship?Visceral and somatic sensory function in functional dyspepsia.Function and dysfunction of the colon and anorectum in adults: working team report of the Swedish Motility Group (SMoG).The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial.Hypersensitivity for capsaicin in patients with functional dyspepsia.In patients with slow transit constipation, the pattern of colonic transit delay does not differentiate between those with and without impaired rectal evacuation.Visualization and quantification of intestinal transit and motor function by real-time tracking of 19F labeled capsules in humans.Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia.
P2860
Q24635181-254434E1-287C-4D41-9488-F191EA1F0C39Q24647522-E792CAFE-A0C1-4EA7-8B6B-71ACA4E9BD7DQ33321445-1D73D487-2849-4E38-8BC9-DCBD113EFF6EQ33586859-A58BF85B-130C-4FCF-B1DF-6C7BE745F576Q33701592-DBE69B89-1CE9-411E-8830-0344990C049CQ34037369-973DECD0-FDCB-4523-A8E4-26F590290523Q34170563-00DB6133-9840-41CD-B75C-43BA27471EB4Q34421382-D63C7A47-621E-4AEB-ABB0-7F17451CAE68Q34453424-244AA391-9796-428D-98B5-C4BA9FED1093Q35565145-802BD316-0D01-4302-99C9-AB757ECC33AAQ35597727-55D43584-13D2-4759-8B22-E087711BA5F3Q35597772-5B06F158-CEA2-46B6-8BDA-3A7B480E6F0DQ35760686-1FAABA22-3FDB-4C33-B2B2-F4627F924D4BQ35882842-F88B4184-7C81-410F-8C44-3E2268390F25Q36455907-9718408F-D103-403A-BD5D-A1505292EFCEQ36476752-C7DD7F27-F9AD-4126-B647-88365A1FFA1BQ37164063-2432B5D6-3DFF-4754-B3DC-1BA12C2DEFDDQ39353081-0A0B303A-ACC8-4F83-ABC7-7F25C82BD270Q39885291-902CEAD2-4965-469C-BAF1-15D767B971A3Q42482132-8E1AA5B2-CD07-4691-85DE-D116C0C539E2Q43340786-EC55630A-8406-4FCA-9EE3-52622E6B75EDQ44327058-C9F5A498-4742-4C29-B24F-FFBD16C9EB7AQ46134684-D5B2B448-DAC2-4ABC-95B5-D07CD7BDB9B3Q46887384-56ECDEB8-9BEF-4B51-85E9-5C2BD7DF414FQ46955025-D460E081-49CD-46F3-BD0A-5265BEBBC9F7Q50666818-F424DCF0-FFD4-40FA-8EB3-A19F1D9DC6FEQ50686179-290F6929-1CC9-4CB9-8BB2-57C17E450A17Q51388257-70C6DD57-A326-479C-8BBC-73907BF7B6F8
P2860
Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
@ast
Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
@en
type
label
Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
@ast
Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
@en
prefLabel
Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
@ast
Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
@en
P2860
P1476
Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
@en
P2093
Camilleri M
P2860
P304
P356
10.1111/J.1365-2982.2004.00516.X
P577
2004-04-01T00:00:00Z